Koot M, Schellekens P T, Mulder J W, Lange J M, Roos M T, Coutinho R A, Tersmette M, Miedema F
Department of Clinical Viro-Immunology, Central Laboratory of the Netherlands Blood Transfusion Service, Amsterdam.
J Infect Dis. 1993 Sep;168(3):733-6. doi: 10.1093/infdis/168.3.733.
The effect of zidovudine on disease progression in asymptomatic human immunodeficiency virus type 1 (HIV-1)-infected men (n = 52) in relation to CD4 T cell numbers, T cell reactivity, and HIV-1 biologic phenotype was studied in a double-blind randomized trial over 2 years. CD4+ cell numbers and T cell reactivity did not differ significantly between the zidovudine- and placebo-treated groups, except for a transient improvement of both parameters in the zidovudine-treated group during the first 9 months. A marked differential efficacy of zidovudine was observed depending on the HIV-1 phenotype present. Zidovudine did not prevent the emergence of high-replicating syncytium-inducing (SI) variants, and clinical progression was observed in persons with SI variants despite zidovudine treatment. In contrast to nontreated HIV-1-infected asymptomatic persons, zidovudine-treated men who did not develop SI variants did not progress to AIDS. The beneficial effect of zidovudine during the asymptomatic phase may be mainly limited to persons who do not develop SI variants in the course of HIV-1 infection.
在一项为期两年的双盲随机试验中，研究了齐多夫定对52名无症状的1型人类免疫缺陷病毒（HIV-1）感染男性疾病进展的影响，该影响与CD4 T细胞数量、T细胞反应性及HIV-1生物学表型有关。除在最初9个月期间齐多夫定治疗组的这两个参数有短暂改善外，齐多夫定治疗组和安慰剂治疗组之间的CD4+细胞数量和T细胞反应性无显著差异。根据存在的HIV-1表型，观察到齐多夫定有明显的疗效差异。齐多夫定不能阻止高复制性合胞体诱导（SI）变异株的出现，并且尽管接受了齐多夫定治疗，但有SI变异株的患者仍出现了临床进展。与未接受治疗的HIV-1感染无症状者相比，未出现SI变异株的接受齐多夫定治疗的男性未进展至艾滋病。齐多夫定在无症状期的有益作用可能主要限于在HIV-1感染过程中未出现SI变异株的患者。
